The Path to Diagnosis: Biopsy and Genetics
At a Glance
MPN-U is diagnosed by combining blood counts, bone marrow findings, mutation testing, and exclusion of reactive causes and other myeloid disorders. No single biopsy finding or mutation establishes the diagnosis, and a negative JAK2, CALR, and MPL panel does not rule it out.
Diagnosing a Myeloproliferative Neoplasm, Unclassifiable (MPN-U) is a process of precision and exclusion. Because MPN-U does not have a single “signature” blood count or mutation, your care team must carefully piece together evidence from your blood, your bone marrow, and your DNA [1][2].
Under the most recent medical guidelines (WHO 2022 and ICC 2022), MPN-U is officially used when you have clear signs of a bone marrow disorder but do not meet the strict criteria for more common types like Polycythemia Vera or Essential Thrombocythemia [3][4]. It also requires the explicit exclusion of other myeloid malignancies, including BCR::ABL1-positive CML, MDS/MPN, and MDS.
The Central Role of Bone Marrow Biopsy
The bone marrow biopsy is a central component of an integrated diagnosis [1]. It allows doctors to see the “factory” where your blood is made. In MPN-U, the marrow typically shows key features, though they are highly variable:
- Hypercellularity: This means your marrow is “too crowded” with cells for your age. In one study of MPN-U patients, 70% had hypercellular marrow [5].
- Megakaryocyte Abnormalities: Megakaryocytes are the large cells that produce platelets. In MPN-U, these cells often appear in “loose clusters” and may have abnormal shapes, described as “giant” or “bulbous” [5][6].
- Fibrosis (Scarring): Your report will list a fibrosis grade from MF-0 (none) to MF-3 (severe). About 59% of MPN-U cases in one series showed some degree of significant scarring in the marrow [5][7]. However, significant scarring should not imply that MF-1 or any fibrosis grade is required; many patients have MF-0.
Decoding Your Genetics
Genetic testing helps prove that your blood cell overproduction is clonal—meaning it stems from a specific mutation in a stem cell, rather than being a temporary reaction to something else [8].
The “Driver” Mutations
Most people with MPN-U carry one of three “driver” mutations that keep the cell-production switch stuck in the “on” position [9]:
- JAK2 V617F: Found in approximately 65% to 72% of MPN-U patients, depending on the cohort.
- CALR: Found in about 12% to 67% of cases where JAK2 is negative.
- MPL: Found in a small minority of cases.
The Role of Next-Generation Sequencing (NGS)
About 22% of MPN-U patients are triple-negative, meaning they do not have any of the three mutations listed above [9]. In these cases, doctors often use Next-Generation Sequencing (NGS). This is a highly sensitive test that “spells out” hundreds of genes at once to look for rarer mutations (such as ASXL1, TET2, or DNMT3A). These mutations may support clonality or provide prognostic information, but they do not confirm an MPN by themselves because they can occur in age-related clonal hematopoiesis or other disorders [8][3]. A negative driver panel does not rule out MPN-U.
Ruling Out “Mimics”
Before settling on an MPN-U diagnosis, your doctor must ensure your blood counts aren’t high due to reactive causes. This is a critical step because these conditions are not cancers and require different treatment [1][10].
- Inflammation: Chronic infections or autoimmune diseases can mimic MPN blood counts [1].
- Iron Deficiency: This can sometimes cause a temporary rise in platelets.
- Smoking or Sleep Apnea: These can cause the body to overproduce red blood cells.
Your Diagnostic Completeness Checklist
When reviewing your medical records or pathology reports, look for these specific details to ensure you have a complete picture of your diagnosis:
| Feature | What to Look For | Why it Matters |
|---|---|---|
| Cellularity | “Hypercellular” or % cellularity | Confirms the marrow is overactive [5]. |
| Fibrosis Grade | MF-0, MF-1, MF-2, or MF-3 | Measures the level of scarring in the marrow [7]. |
| Blast Count | A percentage of immature cells | Must be below thresholds for accelerated or blast-phase disease (usually 10-19% or 20% depending on the classification) [11]. This helps confirm chronic phase, but a normal/low count is not a diagnostic requirement of MPN-U itself. |
| Mutation Status | JAK2, CALR, or MPL results | Identifies the genetic “driver” of the disease [9]. |
| Cytogenetics | Karyotype (e.g., “46, XX” or “46, XY”) | Checks for major chromosomal breaks or swaps [3]. |
| Erythropoietin (EPO) | Level (often low or normal) | Sometimes used in the workup of erythrocytosis to help distinguish MPN-U from other red blood cell issues, though it is not a standalone criterion [12]. |
Common questions in this guide
What does a bone marrow biopsy look for in MPN-U?
Does MPN-U require bone marrow fibrosis?
Which mutations are checked when MPN-U is suspected?
What does triple-negative MPN-U mean, and what is NGS used for?
How are other causes of high blood counts ruled out?
Why is the blast percentage on my marrow report important?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my bone marrow biopsy show 'hypercellularity,' and how does that compare to what is normal for my age?
- 2.Which specific features of my megakaryocytes (the platelet-producing cells) were abnormal or atypical?
- 3.What was my bone marrow fibrosis grade (on the scale of MF-0 to MF-3)?
- 4.Since I am 'triple-negative' for the main mutations, did we perform Next-Generation Sequencing (NGS) to look for other markers of clonality?
- 5.Were reactive causes, such as chronic inflammation or iron deficiency, ruled out before confirming the MPN-U diagnosis?
- 6.What is the percentage of 'blasts' (immature cells) in my marrow, and why is this number important for my prognosis?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (12)
- 1
Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the 'unclassifiable'.
Oganesyan A, Madero-Marroquin R, Patel AA
Current opinion in hematology 2026; (33(2)):45-50 doi:10.1097/MOH.0000000000000907.
PMID: 41496466 - 2
Diagnostic Approach to Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms.
Prakash S, Orazi A
Advances in anatomic pathology 2025; (32(4)):284-298 doi:10.1097/PAP.0000000000000493.
PMID: 40243206 - 3
Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study.
Crane GM, Geyer JT, Thakral B, et al.
American journal of clinical pathology 2024; (162(3)):233-242 doi:10.1093/ajcp/aqae033.
PMID: 38597584 - 4
How I manage myeloproliferative neoplasm-unclassifiable: Practical approaches for 2022 and beyond.
McLornan DP, Hargreaves R, Hernández-Boluda JC, Harrison CN
British journal of haematology 2022; (197(4)):407-416 doi:10.1111/bjh.18087.
PMID: 35191542 - 5
The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.
Gianelli U, Cattaneo D, Bossi A, et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017; (30(2)):169-179 doi:10.1038/modpathol.2016.182.
PMID: 27739437 - 6
Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre.
Deschamps P, Moonim M, Radia D, et al.
British journal of haematology 2021; (193(4)):792-797 doi:10.1111/bjh.17375.
PMID: 33751548 - 7
The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases.
Pizzi M, Croci GA, Ruggeri M, et al.
Cancers 2021; (13(22)) doi:10.3390/cancers13225666.
PMID: 34830822 - 8
Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing.
Maddali M, Venkatraman A, Kulkarni UP, et al.
Annals of hematology 2022; (101(9)):1987-2000 doi:10.1007/s00277-022-04920-w.
PMID: 35840818 - 9
Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.
Maddali M, Kulkarni UP, Ravindra N, et al.
Hematology/oncology and stem cell therapy 2022; (15(2)):13-20 doi:10.1016/j.hemonc.2021.03.002.
PMID: 33789164 - 10
Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options.
Iurlo A, Cattaneo D, Gianelli U, Passamonti F
HemaSphere 2025; (9(12)):e70270 doi:10.1002/hem3.70270.
PMID: 41378161 - 11
Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
Szuber N, Orazi A, Tefferi A
American journal of hematology 2024; (99(7)):1360-1387 doi:10.1002/ajh.27321.
PMID: 38644693 - 12
Polycythemia Vera.
Spivak JL
Current treatment options in oncology 2018; (19(2)):12 doi:10.1007/s11864-018-0529-x.
PMID: 29516275
This page explains how clinicians evaluate MPN-U through bone marrow biopsy and genetic testing for educational purposes only; it does not replace medical advice. Ask a hematologist or pathologist to interpret your results in context.
Get notified when new evidence is published on Chronic myeloproliferative disease, unclassifiable.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.